InfliximabDrug ineffective and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2025年 / 2051卷 / 1期

关键词：

D O I：

10.1007/s40278-025-79667-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：147 / 147

相关论文

共 50 条

[21] Multiple drugsDrug ineffective and off label use: case report
Reactions Weekly, 2021, 1856 (1) : 287 - 287
[22] Dupilumab/triamcinoloneDrug ineffective and off label use: case report
Reactions Weekly, 2021, 1871 (1) : 154 - 154
[23] Multiple drugsVarious toxicities, off-label use and no response to off-label therapy: case report
Reactions Weekly, 2021, 1861 (1) : 232 - 232
[24] Paclitaxel/vemurafenibMyelosuppression and off-label use: case report
Reactions Weekly, 2022, 1888 (1) : 292 - 292
[25] NivolumabFever following off-label use: case report
Reactions Weekly, 2016, 1601 (1) : 186 - 186
[26] FavipiravirNephrotoxicity following off-label use: case report
Reactions Weekly, 2022, 1929 (1) : 283 - 283
[27] BevacizumabRetinal breaks and off-label use: case report
Reactions Weekly, 2022, 1924 (1) : 120 - 120
[28] Mirtazapine/pregabalinDelirium and off-label use: case report
Reactions Weekly, 2024, 2029 (1) : 384 - 384
[29] DexamfetamineHypertension following off-label use: case report
Reactions Weekly, 2021, 1883 (1) : 150 - 150
[30] DexamethasoneHyperglycaemia following off-label use: case report
Reactions Weekly, 2022, 1896 (1) : 173 - 173

← 1 2 3 4 5 →